Business Description
KPC Pharmaceuticals Inc
NAICS : 325412
ISIN : CNE0000015P8
Share Class Description:
SHSE:600422: Class ACompare
Compare
Traded in other countries / regions
600422.China IPO Date
2000-12-06Description
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.47 | |||||
| Equity-to-Asset | 0.55 | |||||
| Debt-to-Equity | 0.15 | |||||
| Debt-to-EBITDA | 1.33 | |||||
| Interest Coverage | 25.59 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.42 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.2 | |||||
| 3-Year EBITDA Growth Rate | 3.2 | |||||
| 3-Year EPS without NRI Growth Rate | 0.5 | |||||
| 3-Year FCF Growth Rate | 5.3 | |||||
| 3-Year Book Growth Rate | 6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 37.3 | |||||
| Future 3-5Y Total Revenue Growth Rate | 11.57 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 51.35 | |||||
| 9-Day RSI | 49.14 | |||||
| 14-Day RSI | 50.24 | |||||
| 6-1 Month Momentum % | -37.16 | |||||
| 12-1 Month Momentum % | -30.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.91 | |||||
| Quick Ratio | 1.51 | |||||
| Cash Ratio | 0.51 | |||||
| Days Inventory | 141.28 | |||||
| Days Sales Outstanding | 139.15 | |||||
| Days Payable | 83.27 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.34 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| 3-Year Dividend Growth Rate | -7.2 | |||||
| Forward Dividend Yield % | 1.34 | |||||
| 5-Year Yield-on-Cost % | 1.38 | |||||
| Shareholder Yield % | 1.29 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 41.82 | |||||
| Operating Margin % | 9.35 | |||||
| Net Margin % | 5.91 | |||||
| FCF Margin % | 7.38 | |||||
| ROE % | 8.3 | |||||
| ROA % | 4.57 | |||||
| ROIC % | 11.1 | |||||
| ROC (Joel Greenblatt) % | 20.47 | |||||
| ROCE % | 10.24 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 24.69 | |||||
| Forward PE Ratio | 15.64 | |||||
| PE Ratio without NRI | 20.48 | |||||
| Shiller PE Ratio | 25.24 | |||||
| Price-to-Owner-Earnings | 31.66 | |||||
| PEG Ratio | 3.3 | |||||
| PS Ratio | 1.5 | |||||
| PB Ratio | 2 | |||||
| Price-to-Tangible-Book | 2.25 | |||||
| Price-to-Free-Cash-Flow | 20.13 | |||||
| Price-to-Operating-Cash-Flow | 18.33 | |||||
| EV-to-EBIT | 16.47 | |||||
| EV-to-EBITDA | 16.47 | |||||
| EV-to-Revenue | 1.34 | |||||
| EV-to-FCF | 18.16 | |||||
| Price-to-Projected-FCF | 1.77 | |||||
| Price-to-DCF (Earnings Based) | 1.77 | |||||
| Price-to-DCF (FCF Based) | 1.71 | |||||
| Price-to-Median-PS-Value | 1.07 | |||||
| Price-to-Graham-Number | 1.43 | |||||
| Price-to-Net-Current-Asset-Value | 3.61 | |||||
| Earnings Yield (Greenblatt) % | 6.07 | |||||
| FCF Yield % | 5.02 | |||||
| Forward Rate of Return (Yacktman) % | 0.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
KPC Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 7,549.712 | ||
| EPS (TTM) (Â¥) | 0.593 | ||
| Beta | 0.79 | ||
| Volatility % | 31.09 | ||
| 14-Day RSI | 50.24 | ||
| 14-Day ATR (Â¥) | 0.543627 | ||
| 20-Day SMA (Â¥) | 15.1625 | ||
| 12-1 Month Momentum % | -30.9 | ||
| 52-Week Range (Â¥) | 11.92 - 24.11 | ||
| Shares Outstanding (Mil) | 756.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
KPC Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
KPC Pharmaceuticals Inc Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
KPC Pharmaceuticals Inc Frequently Asked Questions
What is KPC Pharmaceuticals Inc(SHSE:600422)'s stock price today?
The current price of SHSE:600422 is ¥14.64. The 52 week high of SHSE:600422 is ¥24.11 and 52 week low is ¥11.92.
When is next earnings date of KPC Pharmaceuticals Inc(SHSE:600422)?
The next earnings date of KPC Pharmaceuticals Inc(SHSE:600422) is .
Does KPC Pharmaceuticals Inc(SHSE:600422) pay dividends? If so, how much?
The Dividend Yield %  of KPC Pharmaceuticals Inc(SHSE:600422) is 1.34% (As of Today), Highest Dividend Payout Ratio of KPC Pharmaceuticals Inc(SHSE:600422) was 0.82. The lowest was 0.16. And the median was 0.48. The  Forward Dividend Yield % of KPC Pharmaceuticals Inc(SHSE:600422) is 1.34%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers